26.54
price up icon3.11%   0.80
after-market After Hours: 26.65 0.11 +0.41%
loading
Moderna Inc stock is traded at $26.54, with a volume of 7.99M. It is up +3.11% in the last 24 hours and down -18.74% over the past month. Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$25.74
Open:
$26.5
24h Volume:
7.99M
Relative Volume:
0.74
Market Cap:
$9.74B
Revenue:
$5.06B
Net Income/Loss:
$-2.22B
P/E Ratio:
-4.5601
EPS:
-5.82
Net Cash Flow:
$-3.96B
1W Performance:
+5.36%
1M Performance:
-18.74%
6M Performance:
-50.29%
1Y Performance:
-75.40%
1-Day Range:
Value
$26.45
$27.88
1-Week Range:
Value
$23.30
$27.88
52-Week Range:
Value
$23.15
$170.47

Moderna Inc Stock (MRNA) Company Profile

Name
Name
Moderna Inc
Name
Phone
(617) 714-6500
Name
Address
325 BINNEY STREET, CAMBRIDGE
Name
Employee
5,800
Name
Twitter
@moderna_tx
Name
Next Earnings Date
2025-02-14
Name
Latest SEC Filings
Name
MRNA's Discussions on Twitter

Compare MRNA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
MRNA
Moderna Inc
26.54 9.74B 5.06B -2.22B -3.96B -5.82
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.42 124.91B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
587.85 60.05B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
594.65 35.88B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.97 29.83B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.13 24.58B 3.81B -644.79M -669.77M -6.24

Moderna Inc Stock (MRNA) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-13-25 Initiated Citigroup Neutral
Feb-18-25 Downgrade Barclays Overweight → Equal Weight
Jan-29-25 Downgrade Goldman Buy → Neutral
Dec-18-24 Downgrade Argus Buy → Hold
Dec-10-24 Resumed BofA Securities Underperform
Nov-19-24 Initiated Berenberg Hold
Nov-18-24 Upgrade HSBC Securities Hold → Buy
Nov-15-24 Initiated Wolfe Research Underperform
Oct-17-24 Initiated Bernstein Mkt Perform
Sep-13-24 Downgrade JP Morgan Neutral → Underweight
Sep-13-24 Downgrade Jefferies Buy → Hold
Sep-13-24 Downgrade Oppenheimer Outperform → Perform
Aug-28-24 Upgrade HSBC Securities Reduce → Hold
Aug-07-24 Upgrade Deutsche Bank Sell → Hold
Aug-05-24 Downgrade RBC Capital Mkts Outperform → Sector Perform
Feb-26-24 Downgrade HSBC Securities Hold → Reduce
Jan-02-24 Upgrade Oppenheimer Perform → Outperform
Nov-29-23 Initiated Canaccord Genuity Hold
Nov-03-23 Upgrade HSBC Securities Reduce → Hold
Nov-02-23 Downgrade Deutsche Bank Hold → Sell
Aug-04-23 Downgrade TD Cowen Outperform → Market Perform
Aug-03-23 Downgrade Deutsche Bank Buy → Hold
Jul-24-23 Initiated William Blair Mkt Perform
Jul-14-23 Initiated HSBC Securities Reduce
Jun-26-23 Upgrade UBS Neutral → Buy
Apr-26-23 Initiated Guggenheim Neutral
Mar-13-23 Upgrade TD Cowen Market Perform → Outperform
Mar-02-23 Initiated RBC Capital Mkts Outperform
Feb-24-23 Downgrade SVB Securities Market Perform → Underperform
Dec-19-22 Upgrade Jefferies Hold → Buy
Dec-14-22 Downgrade Chardan Capital Markets Buy → Neutral
Oct-21-22 Upgrade SVB Leerink Underperform → Mkt Perform
Sep-08-22 Upgrade Deutsche Bank Hold → Buy
Feb-01-22 Upgrade Redburn Sell → Neutral
Jan-26-22 Upgrade Deutsche Bank Sell → Hold
Jan-21-22 Upgrade BofA Securities Underperform → Neutral
Jan-21-22 Initiated UBS Neutral
Dec-07-21 Initiated Cowen Market Perform
Nov-09-21 Initiated Wolfe Research Outperform
Oct-22-21 Initiated Deutsche Bank Sell
Oct-15-21 Upgrade Piper Sandler Neutral → Overweight
Aug-06-21 Downgrade Oppenheimer Outperform → Perform
Aug-06-21 Downgrade Piper Sandler Overweight → Neutral
Jul-15-21 Reiterated Jefferies Hold
Feb-01-21 Downgrade BofA Securities Neutral → Underperform
Dec-16-20 Downgrade Jefferies Buy → Hold
Dec-16-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Dec-09-20 Downgrade Needham Buy → Hold
Nov-23-20 Initiated Wells Fargo Equal Weight
Nov-17-20 Downgrade BMO Capital Markets Outperform → Market Perform
Sep-08-20 Downgrade SVB Leerink Mkt Perform → Underperform
Jul-23-20 Initiated SVB Leerink Mkt Perform
Jul-20-20 Downgrade JP Morgan Overweight → Neutral
Jul-13-20 Initiated Jefferies Buy
Jun-30-20 Initiated Argus Buy
Jun-08-20 Initiated Barclays Overweight
Apr-30-20 Initiated BMO Capital Markets Outperform
Mar-05-20 Downgrade BofA/Merrill Buy → Neutral
Dec-03-19 Resumed BofA/Merrill Buy
Oct-25-19 Initiated ROTH Capital Buy
Apr-05-19 Initiated Chardan Capital Markets Buy
View All

Moderna Inc Stock (MRNA) Latest News

pulisher
Apr 23, 2025

Novavax: New COVID-19 Vaccine on Track for FDA Approval - Inc.com

Apr 23, 2025
pulisher
Apr 23, 2025

SK bioscience wins patent case against Moderna in South Korea - Social News XYZ

Apr 23, 2025
pulisher
Apr 23, 2025

TD Cowen Adjusts Moderna Price Target to $30 From $35, Maintains Hold Rating - marketscreener.com

Apr 23, 2025
pulisher
Apr 23, 2025

Vaccine-wary Slovak PM pauses COVID-19 shot purchases pending review - marketscreener.com

Apr 23, 2025
pulisher
Apr 23, 2025

Novavax says its COVID-19 shot is on track for full FDA approval after delay - Value The Markets

Apr 23, 2025
pulisher
Apr 23, 2025

Moderna (NASDAQ:MRNA) Given Market Perform Rating at William Blair - MarketBeat

Apr 23, 2025
pulisher
Apr 23, 2025

Canada Pension Plan Investment Board Raises Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat

Apr 23, 2025
pulisher
Apr 22, 2025

More Downside For Moderna Before The Breakthrough (NASDAQ:MRNA) - Seeking Alpha

Apr 22, 2025
pulisher
Apr 22, 2025

Moderna Can't Buy Time To Defend COVID Vax UPC Claim - Law360

Apr 22, 2025
pulisher
Apr 22, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 22, 2025
pulisher
Apr 22, 2025

Guggenheim Capital LLC Cuts Stake in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat

Apr 22, 2025
pulisher
Apr 22, 2025

Altshuler Shaham Ltd Boosts Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat

Apr 22, 2025
pulisher
Apr 21, 2025

What to Expect From Moderna's Q1 2025 Earnings Report - Nasdaq

Apr 21, 2025
pulisher
Apr 21, 2025

Scotia Capital Inc. Has $284,000 Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat

Apr 21, 2025
pulisher
Apr 21, 2025

Brokerages Set Moderna, Inc. (NASDAQ:MRNA) Target Price at $58.70 - MarketBeat

Apr 21, 2025
pulisher
Apr 21, 2025

Bridgewater Associates LP Makes New Investment in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat

Apr 21, 2025
pulisher
Apr 21, 2025

Wolfe Research Adjusts Moderna Price Target to $20 From $25, Keeps Underperform Rating - marketscreener.com

Apr 21, 2025
pulisher
Apr 21, 2025

What To Expect From Moderna's Q1 2025 Earnings Report - Barchart.com

Apr 21, 2025
pulisher
Apr 21, 2025

Preventive Vaccines Market Forecast 2025-2032- Growth - openPR.com

Apr 21, 2025
pulisher
Apr 20, 2025

Where Will Moderna Be in 5 Years? - Yahoo Finance

Apr 20, 2025
pulisher
Apr 20, 2025

Advisory Services Network LLC Purchases 16,555 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat

Apr 20, 2025
pulisher
Apr 20, 2025

Q1 Earnings Forecast for Moderna Issued By Leerink Partnrs - MarketBeat

Apr 20, 2025
pulisher
Apr 19, 2025

Lobbying Update: $60,000 of MODERNA INC. lobbying was just disclosed - Nasdaq

Apr 19, 2025
pulisher
Apr 18, 2025

Russell Investments Group Ltd. Increases Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat

Apr 18, 2025
pulisher
Apr 18, 2025

Bank of Montreal Can Trims Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat

Apr 18, 2025
pulisher
Apr 18, 2025

The Gutierrez Co. Sued Over Mold, Water Damage at Moderna Site — Boston Business Journal - Boston Real Estate Times

Apr 18, 2025
pulisher
Apr 18, 2025

Moderna sues construction firm claiming leaks, mold at new drug plant - NBC Boston

Apr 18, 2025
pulisher
Apr 18, 2025

Water leaks, mold plague Moderna's new manufacturing site, lawsuit claims - The Business Journals

Apr 18, 2025
pulisher
Apr 17, 2025

Quinn Opportunity Partners LLC Purchases Shares of 16,500 Moderna, Inc. (NASDAQ:MRNA) - MarketBeat

Apr 17, 2025
pulisher
Apr 17, 2025

Moderna (MRNA) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance

Apr 17, 2025
pulisher
Apr 17, 2025

US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years - Benzinga

Apr 17, 2025
pulisher
Apr 17, 2025

Invesco Ltd. Acquires 979,858 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat

Apr 17, 2025
pulisher
Apr 17, 2025

Moderna Says New Drug Plant Riddled With Defects, Mold - Law360

Apr 17, 2025
pulisher
Apr 17, 2025

Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Legal & General Group Plc - MarketBeat

Apr 17, 2025
pulisher
Apr 17, 2025

Moderna (MRNA) Leads Healthcare Short Interest in March - GuruFocus

Apr 17, 2025
pulisher
Apr 17, 2025

Lansdowne Partners UK LLP Acquires New Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat

Apr 17, 2025
pulisher
Apr 16, 2025

Neuberger Berman Group LLC Reduces Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat

Apr 16, 2025
pulisher
Apr 16, 2025

Bloom Energy, Rogers, 3D Systems, Moderna, and EchoStar Stocks Trade Down, What You Need To Know - The Globe and Mail

Apr 16, 2025
pulisher
Apr 16, 2025

Moderna permitted to start commercial mRNA vaccine manufacture in UK - The Pharma Letter

Apr 16, 2025
pulisher
Apr 16, 2025

Leerink Partners Adjusts Moderna Price Target to $23 From $27, Maintains Underperform Rating - marketscreener.com

Apr 16, 2025
pulisher
Apr 16, 2025

Moderna Co-Founder and MIT Legend Strengthens Decoy Therapeutics Drug Development Team - Stock Titan

Apr 16, 2025
pulisher
Apr 16, 2025

MRNA Based Vaccines and Therapeutics Therapeutics Market Size - openPR.com

Apr 16, 2025
pulisher
Apr 16, 2025

Renaissance Technologies LLC Grows Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat

Apr 16, 2025
pulisher
Apr 15, 2025

APG Asset Management N.V. Buys 203,792 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat

Apr 15, 2025
pulisher
Apr 15, 2025

FDA Special Assistant Høeg’s Vaccine Concerns On Display At ACIP - insights.citeline.com

Apr 15, 2025
pulisher
Apr 15, 2025

Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Shelton Capital Management - MarketBeat

Apr 15, 2025
pulisher
Apr 15, 2025

Stocks Edge Up On Strong Bank Earnings, Netflix Soars, Dollar Rebounds: What's Driving Markets Tuesday? - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Goldman Sachs Adjusts Moderna's Price Target to $35 From $49, Keeps Neutral Rating - MarketScreener

Apr 15, 2025

Moderna Inc Stock (MRNA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.13
price down icon 0.69%
$70.80
price down icon 0.62%
$31.69
price down icon 1.55%
$33.23
price up icon 21.50%
$114.83
price up icon 9.70%
biotechnology ONC
$249.13
price down icon 1.44%
Cap:     |  Volume (24h):